1412P Palliative stents in a large cohort of advanced gastroesophageal cancers (GOC): Factors associated with long term survival

Abstract

PS of 0 (n¼39, 15.18%) or 1 (n¼203, 78.99%). The treatment of apatinib was mainly first-line treatment (n¼103, 40.08%), second-line treatment (n¼64, 24.90%), and adjuvant treatment (n¼42, 16.34%). The starting dose of apatinib was 250mg in 132 patients and 500mg in 125 patients. The treatment regimens were: apatinib combined with chemotherapy drugs (178/257), apatinib monotherapy (64/257), apatinib combined with chemotherapy drugs plus PD-1 antibody drug (8/275), and apatinib combined with PD-1 antibody drug (7/275). Thirty-three patients achieved partial response, 69 patients achieved stable disease, and 26 patients had progressive disease, and no CR was achieved, illustrating an ORR of 25.78% and a DCR of 79.69%. During the treatment, the overall incidence of adverse events was 70.82%. The most common adverse events were hypertension (32.68%), leukopenia (26.46%), hand-foot syndrome (25.29%), neutropenia (20.23%), etc.Conclusions: This real-world research showed current treatment status and provided preliminary evidence for the efficacy and safety of apatinib in the treatment of gastric cancer in China. More data would be analyzed and reported in future.[ChiCTR2000035597]Legal entity responsible for the study: The authors.

Survival of patients after stent placement and chemotherapy in the treatment of esophageal cancer: A literature review

“…[22] This corroborates recently published data on a real-world cohort of patients. [11] Although this review might highlight the lack evidence in literature to assure survival benefit of chemotherapy in patients which underwent to esophageal stenting, it should be seen in the light of its limitations. The studies were significantly heterogeneous in inclusion criteria and treatment regimen, which significantly impairs a proper comparison amongst them.…”

“…In a recent study, authors suggest that post-stent systemic treatment is associated with longer survival. [11] It is known that post-stent local radiotherapy does not offer improved survival and actinic esophagitis can occur in up to 28% of patients. On the other hand, very little is known about the survival related to systemic treatment in patients who received stents in trials.…”